ArticlemBio2021
Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 38 citations in OpenAlex.
- AI-driven big data analysis and predictive modeling of infectious disease immunity: from correlates to causal, multiscale understanding.Archives of microbiology · 2026Review
- Vaccination and hybrid immunity is associated with SARS-CoV-2 protection but not shedding duration in rural Guatemalan households.Research square · 2026Article
- A systems biology approach to define SARS-CoV-2 correlates of protection.NPJ vaccines · 2025Article
- The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis.Vaccines · 2025Article
- Are older adults living with HIV more susceptible to omicron infection compared to their HIV-negative peers in China: a cross-sectional study.Frontiers in public health · 2025Article
- SIV/SARS-CoV-2 coinfection in rhesus macaques impacts viral shedding, host immunity, the microbiome, and viral evolution.Frontiers in immunology · 2025Article
- NK cells modulate in vivo control of SARS-CoV-2 replication and suppression of lung damage.PLoS pathogens · 2024Article
- Article
- Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.Zoological research · 2024Review
- The immune response to SARS-CoV-2 in people with HIV.Cellular & molecular immunology · 2024Review
- Ensemble modeling of SARS-CoV-2 immune dynamics in immunologically naïve rhesus macaques predicts that potent, early innate immune responses drive viral elimination.Frontiers in immunology · 2024Article
- Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice.Microbiology spectrum · 2023Article
- ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.Nature immunology · 2023Article
- Innate immune cell activation causes lung fibrosis in a humanized model of long COVID.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Pre-clinical models to define correlates of protection for SARS-CoV-2.Frontiers in immunology · 2023Review
- Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.Cell · 2022Article
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination.The Journal of infectious diseases · 2022Article
- Article
- Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.JCI insight · 2022Article
Corrections and comments
- Update of
Authors and funding
24 authors at 2 institutions in 1 country.
Kim J HasenkrugLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Friederike FeldmannRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Lara MyersLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Mario L SantiagoDepartments of Medicine, Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Kejun GuoDepartments of Medicine, Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Bradley S BarrettDepartments of Medicine, Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Kaylee L MickensDepartments of Medicine, Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Aaron CarmodyResearch Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Atsushi OkumuraLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Deepashri RaoLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Madison M CollinsLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Ronald J MesserLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Jamie LovaglioRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Carl ShaiaRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Rebecca RosenkeRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Neeltje van DoremalenLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Chad ClancyRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Greg SaturdayRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Patrick HanleyRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Brian J SmithRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Kimberly Meade-WhiteLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
W Lesley ShupertLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
David W HawmanLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
Heinz FeldmannLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.
National Institutes of Health · USUniversity of Colorado Denver · US
Funding
SARS-CoV-2: Pathogenesis and Countermeasure DevelopmentZIAAI001300 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FELDMANN, HEINRICH · 2020 to 2023
$3.3MDivision of Infectious Diseases, University of ColoradoDivision of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)
Abstract
Severe coronavirus disease 2019 (COVID-19) has been associated with T cell lymphopenia, but no causal effect of T cell deficiency on disease severity has been established. To investigate the specific role of T cells in recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, we studied rhesus macaques that were depleted of either CD4
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19FemaleImmunologic MemoryLymphocyte DepletionLymphopeniaMacaca mulattaMaleSARS-CoV-2Antibodies, NeutralizingAntibodies, Viralmacaqueneutralizing antibodiesSARS-CoV-2T cells
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.